1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Myanmar Pharmaceuticals and Healthcare Report Q4 2016

Myanmar Pharmaceuticals and Healthcare Report Q4 2016

  • October 2016
  • -
  • Business Monitor International
  • -
  • 53 pages

Includes 3 FREE quarterly updates
BMI View:

Myanmar's plan to introduce a maximum retail price for pharmaceuticals will not be fully implemented. The country's Food and Drug Administration lacks the regulatory capacity to enforce such a scheme as it struggles to address existing challenges such as the widespread sale of counterfeit medicines. Moreover, patient demand for low-value medicines that are yet to be registered points to structural problems within the medical system. Furthermore, access to medicines at public facilities and affordability constraints will not be adequately mitigated with the implementation of price controls.

Headline Expenditure Projections

- Pharmaceutical sales: MMK458bn (USD391mn) in 2015 to MMK525bn (USD409mn) in 2015; +14.6% in local currency terms and +4.5% in US dollar terms. Forecast broadly in line with previous quarter.

- Healthcare Expenditure: MMK1,608bn (USD1.4bn) in 2015 to MMK1,796bn (USD1.4bn) in 2016; +11.6% in local currency terms and 1.7% in US dollar terms. Absolute figures revised upwards from previous quarter. However, growth forecast remains broadly unchanged.

Table Of Contents

Myanmar Pharmaceuticals and Healthcare Report Q4 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Myanmar 2014-2020) 7
SWOT 9
Industry Forecast 10
Pharmaceutical Market Forecast 10
Table: Pharmaceutical Sales, Historical Data And Forecasts (Myanmar 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Myanmar 2012-2020) 16
Pharmaceutical Trade Forecast 17
Table: Pharmaceutical Trade Data And Forecasts (Myanmar 2014-2020) 18
Table: Pharmaceutical Trade Data And Forecasts local currency (Myanmar 2014-2020) 18
Industry Risk/Reward Index 19
Asia Pacific Risk/Reward Index - Q4 2016 19
Myanmar Risk/Reward Index 26
Rewards 26
Risks 26
Regulatory Review 28
Intellectual Property Regime 28
Pricing Regime 28
Reimbursement Regime 29
Market Overview 30
Healthcare Sector 30
Research and Development 32
Clinical Trials 32
Epidemiology 32
Competitive Landscape 35
Table: Multinational Market Activity 35
Company Profile 36
Fame Pharmaceutical 36
Mega Lifesciences 38
Table: More Clients In Myanmar 39
Demographic Forecast 42
Table: Population Headline Indicators (Myanmar 1990-2025) 43
Table: Key Population Ratios (Myanmar 1990-2025) 43
Table: Urban/Rural Population and Life Expectancy (Myanmar 1990-2025) 44
Table: Population By Age Group (Myanmar 1990-2025) 44
Table: Population By Age Group % (Myanmar 1990-2025) 45
Glossary 47
Methodology 49
Pharmaceutical Expenditure Forecast Model 49
Healthcare Expenditure Forecast Model 49
Notes On Methodology 50
Risk/Reward Index Methodology 51
Index Overview 52
Table: Pharmaceutical Risk/Reward Index Indicators 52
Indicator Weightings 53

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.